

November 10, 2022

To **BSE Limited** The Corporate Relationship Dept. P.J. Towers, Dalal Street Mumbai-400 001 Scrip Code: 500214 То

National Stock Exchange of India Limited Exchange Plaza, C-1, Block- G, Bandra Kurla Complex, Bandra (East), Mumbai-400 051 Scrip Code: IONEXCHANG

#### Sub: Submission of Analyst / Investor Presentation

Dear Sir/ Madam,

Pursuant to Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed presentation being made to Analyst / Institutional Investor to discuss the Financial performance of the Company for the second quarter and half year ended September 30, 2022.

The aforesaid information is also disclosed on website of the company i.e. <u>www.ionexchangeglobal.com</u>.

Kindly take the information on record.

Thanking You

Yours faithfully, For Ion Exchange (India) Limited

Milind Puranik Company Secretary

> ION EXCHANGE (INDIA) LTD. | CIN: L74999MH1964PLC014258 Regd. Office: Ion House, Dr. E. Moses Road, Mahalaxmi, Mumbai - 400 011, India.

Board: +91 22 6231 2000 | Fax: +91 22 2493 8737 | E-mail: ieil@ionexchange.co.in | Web: www.ionindia.com

Offices: Bengaluru | Bhubaneswar | Chandigarh | Chennai | Hyderabad | Kolkata | Lucknow | New Delhi | Pune | Vadodara | Vashi | Visakhapatnam



EARNINGS PRESENTATION – Q2 / H1-FY23



#### **Executive Summary**

FY22: Operating Income\* INR 15,769 Mn

> FY22: Operating EBITDA\* INR 2,132 Mn

> > \*Consolidated

FY22: PAT\* INR 1,617 Mn

#### **OVERVIEW**

- Ion Exchange (India) Ltd (Ion Exchange), formed in 1964, is a pioneer in water, waste water treatment & environment solutions and caters to various industries, institutions, homes & communities.
- Headquartered in Mumbai, the company has seven manufacturing & assembly facilities across India, and one each in Bangladesh, UAE, Bahrain and Indonesia. It also has presence across other key geographies.

#### FY22 REVENUE & BUSINESS MIX (%)\*

- Engineering (58%) Provides comprehensive and integrated services and solutions in water & waste water treatment including Sea Water desalination, Recycle and Zero liquid discharge plants to diverse industries.
- Chemicals (34%) Provides a comprehensive range of resins, speciality chemicals and customized chemical treatment programmes for water, non-water and specialty applications.
- Consumer Products (8%) Caters to individuals, hotels, spas, educational institutions, hospitals, laboratories, railway and defence establishments providing safe drinking water and a clean environment.


#### MARQUEE CLIENTS

- Industrial NTPC, NPC, Reliance, IOCL, JSW, CPCL, L&T, Arcelormittal Nippon Steel, Nayara Energy, IRCTC, BHEL, Tata Group.
- Institutional Leela, Military Engineering Services, Taj Hotels, Holiday Inn, Hyatt Regency, Oberoi Hotels, Apollo Hospitals, Escorts Heart Institute, DLF, Puravankar.
- International Cargill, Technip France, Unilever Group, Jurong, Thyssenkrupp (Uhde), Jacobs, Kawasaki, Mitsubishi, PDO Oman, Emirates Steel, IKPP Indonesia.


# **Company Overview**

- Ion Exchange was originally formed as a subsidiary of Permutit, UK in 1964. It became a wholly owned Indian company in 1985. The company is currently in its 59<sup>th</sup> Year of operations.
- The company has expanded its footprints globally and possesses a diversified product range. It offers one stop water and non-water treatment solutions catering to diverse segments like infrastructure, industry, institutions, municipalities, homes and communities, urban and rural.
- The company offers a wide range of solutions across the water cycle from pretreatment to process water treatment, waste water treatment, recycle, zero liquid discharge, sewage treatment, packaged drinking water, sea water desalination etc.
- The company is also engaged in manufacturing ion exchange resins, membranes, speciality chemicals for water and waste water treatment as well as non-water applications.
- It has two facilities for in-house R&D and two applications and testing centers.
- The company has over 50 patents to their credit and 100+ products commercialized.
- The company has a global presence apart from presence in major cities in India with 36+ sales & service centers and 100+ Channel Partners.
- The company exports to Africa, Japan, Middle East, Russia, South East Asia, Europe, UK, USA, Canada and neighbouring countries.

#### REVENUE BREAKUP (FY22)\*



#### GEOGRAPHICAL BREAKUP (FY22)\*



# Q2 / H1-FY23 Financial Highlights

Q2-FY2:	3 Performance (Star	ndalone)	Q2-FY23	Performance (Cons	olidated)
INR 4,177 Mn Operating Income	INR 440 Mn Operating EBITDA	<b>10.53%</b> Operating EBITDA Margins	INR 4,476 Mn Operating Income	INR 533 Mn Operating EBITDA	<b>11.91%</b> Operating EBITDA Margins
INR 341 Mn Net Profit	<b>8.16%</b> PAT Margins	INR 27.70 /Share Diluted EPS	<b>INR 387 Mn</b> Net Profit	<b>8.65%</b> PAT Margins	INR 32.89 /Share Diluted EPS
H1-FY23	3 Performance (Star	idalone)	H1-FY23	Performance (Cons	olidated)
INR 7,757 Mn Operating Income	INR 770 Mn Operating EBITDA	<b>9.93%</b> Operating EBITDA Margins	INR 8,300 Mn Operating Income	INR 862 Mn Operating EBITDA	<b>10.39%</b> Operating EBITDA Margins
INR 652 Mn Net Profit	<b>8.41%</b> PAT Margins	INR 53.00 /Share Diluted EPS	<b>INR 661 Mn</b> Net Profit	7.96% PAT Margins	INR 56.52 /Share Diluted EPS

# Q2 / H1-FY23 Operational Highlights

#### ENGINEERING

- The company witnessed steady order flows both in domestic and international market.
- Regarding Sri Lanka order, the execution remained affected due to the ongoing uncertainties in Sri Lanka.
- > Execution of the UP Jal Nigam Project is progressing satisfactorily, and revenue has been recognized based on work completion.
- > The Company is well placed to undertake significantly increased pace of execution in the ensuing quarters.

#### CHEMICALS

- > The domestic segment continued to record steady growth.
- The export volumes remained constrained.
- > The segment witnessed improved margins in spite of the impact of rising US dollar rates on input prices.

#### **CONSUMER PRODUCTS**

Investments in infrastructure and new products is giving encouraging results. The company expects the segment to sustain its growth momentum.

#### ENGINEERING ORDER BOOK AND PIPELINE (As on 30th September, 2022)

Engineering projects <sup>^</sup>
~ INR 1,458 Cr

Outstanding Sri Lanka ~ INR 256 Cr Outstanding UP SWSM ~ INR 1,081 Cr Total Orderbook ~ INR 2,795 Cr **Bid Pipeline** ~ INR 8,025 Cr


^Excluding Sri Lanka Order & UP SWSM

## Quarterly Standalone Financial Performance

INCOME STATEMENT (INR MN)	Q2-FY23	Q2-FY22	Y-o-Y	Q1-FY23	Q-o-Q
Operating Income	4,177	3,647	14.5%	3,580	16.7%
Expenses	3,737	3,250	15.0%	3,251	14.9%
Operating EBITDA	440	397	10.8%	329	33.7%
Operating EBITDA Margins (%)	10.53%	10.89%	(36) Bps	9.19%	134 Bps
Depreciation	69	67	3.0%	68	1.5%
Finance Cost	16	19	(15.8)%	16	NA
Other Income	109	99	10.1%	179	(39.1)%
РВТ	464	410	13.2%	424	9.4%
Тах	123	109	12.8%	113	8.8%
Profit After Tax	341	301	13.3%	311	9.6%
PAT Margins (%)	8.16%	8.25%	(9) Bps	8.69%	(53) Bps
Other Comprehensive Income	(4)	2	NA	(3)	(33.3)%
Total Comprehensive Income	337	303	11.2%	308	9.4%
Diluted EPS (INR)#	27.70	24.47	13.2%	25.31	9.4%

#Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 23, 73, 614)

## Quarterly Standalone Segmental Breakup



# Half Yearly Standalone Financial Performance

INCOME STATEMENT (INR MN)	H1-FY23	H1-FY22	Y-o-Y
Operating Income	7,757	6,653	16.6%
Expenses	6,987	5,891	18.6%
Operating EBITDA	770	762	1.0%
Operating EBITDA Margins (%)	9.93%	11.45%	(152) Bps
Depreciation	137	134	2.2%
Finance Cost	32	40	(20.0)%
Other Income	287	197	45.7%
РВТ	888	785	13.1%
Тах	236	210	12.4%
Profit After Tax	652	575	13.4%
PAT Margins (%)	8.41%	8.64%	(23) Bps
Other Comprehensive Income	(7)	5	NA
Total Comprehensive Income	645	580	11.2%
Diluted EPS (INR)#	53.00	46.79	13.3%

#Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 23, 73, 614)

4)

# Half Yearly Standalone Segmental Breakup

H1-FY22

H1-FY23



H1-FY22

H1-FY23

Э


(20)


## Quarterly Consolidated Financial Performance

Q2-FY23	Q2-FY22	Y-o-Y	Q1-FY23	Q-o-Q
4,476	3,782	18.4%	3,824	17.1%
3,943	3,385	16.5%	3,495	12.8%
533	397	34.3%	329	62.0%
11.91%	10.50%	141 Bps	8.60%	331 Bps
72	70	2.9%	71	1.4%
23	25	(8)%	22	4.5%
81	79	2.5%	149	(45.6)%
519	381	36.2%	385	34.8%
1	3	(66.7)%	5	(80.0)%
133	112	18.8%	116	14.7%
387	272	42.3%	274	41.2%
8.65%	7.19%	146 Bps	7.17%	148 Bps
7	9	(22.2)%	5	40.0%
394	281	40.2%	279	41.2%
32.89	23.13	42.2%	23.64	39.1%
	4,476 3,943 533 11.91% 72 23 23 81 519 1 387 1 387 8.65% 7 394	4,4763,7823,9433,38539433,38553339753339711.91%10.50%7270732581795193811331123872728.65%7.19%394281	4,4763,78218.4%3,9433,38516.5%53339734.3%53339734.3%11.91%10.50%141 Bps72702.9%2325(8)%81792.5%51938136.2%13311218.8%38727242.3%8.65%7.19%146 Bps79(22.2)%39428140.2%	4,4763,78218.4%3,8243,9433,38516.5%3,49553339734.3%32953339734.3%32911.91%10.50%141 Bps8.60%72702.9%712325(8)%2281792.5%14951938136.2%38513311218.8%11638727242.3%2748.65%7.19%146 Bps7.17%39428140.2%279

#Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 23,73,614) and shares held by Subsidiary companies: (No. of Shares- 4,37,874)

# Quarterly Consolidated Segmental Breakup











# Half Yearly Consolidated Financial Performance


INCOME STATEMENT (INR MN)	H1-FY23	H1-FY22	Y-o-Y
Operating Income	8,300	6,923	19.9%
Expenses	7,438	6,168	20.6%
Operating EBITDA	862	755	14.2%
Operating EBITDA Margins (%)	10.39%	10.91%	(52) Bps
Depreciation	143	140	2.1%
Finance Cost	45	52	(13.5)%
Other Income	230	152	51.3%
РВТ	904	715	26.4%
Share of Profit of equity accounted Investee	6	4	50.0%
Тах	249	214	16.4%
Profit After Tax	661	505	30.9%
PAT Margins (%)	7.96%	7.29%	67 Bps
Other Comprehensive Income	12	11	9.1%
Total Comprehensive Income	673	516	30.4%
Diluted EPS (INR)#	56.52	43.27	30.6%


#Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 23,73,614) and shares held by Subsidiary companies: (No. of Shares- 4,37,874)

# Half Yearly Consolidated Segmental Breakup









# HISTORICAL FINANCIAL OVERVIEW

# Historical Standalone Financial Performance

INCOME STATEMENT (INR MN)	FY19	FY20	FY21	FY22	H1-FY23
Operating Income	11,023	14,072	14,018	15,094	7,757
Expenses	10,110	12,862	12,067	13,123	6,987
Operating EBITDA	913	1,210	1,951	1,971	770
Operating EBITDA Margins (%)	8.28%	8.60%	13.92%	13.06%	9.93%
Depreciation	181	221	261	268	137
Finance Cost	162	132	99	76	32
Other Income	441	485	368	461	287
РВТ	1,011	1,342	1,959	2,088	888
Тах	345	351	499	545	236
Profit After Tax	666	991	1,460	1,542	652
PAT Margins (%)	6.04%	7.04%	10.42%	10.22%	8.41%
Other Comprehensive Income	(5)	(9)	9	(15)	(7)
Total Comprehensive Income	661	982	1,469	1,527	645
Diluted EPS (INR)	55.47*	81.85#	118.75 <sup>@</sup>	125.44 <sup>@</sup>	53.00 <sup>@</sup>

\*Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. No. of Shares- 26,62,914

#Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. No. of Shares-23,68,939

@Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 23, 73, 614)

# Historical Standalone Balance Sheet

PARTICULARS (INR MN)	FY21	FY22	H1-FY23	PARTICULARS (INR MN)	FY21	FY22	H1-FY23
EQUITIES & LIABILITIES				ASSETS			
Equity				Non-Current Assets			
(A) Equity Share Capital	147	147	147	(A) Property, Plant and Equipment	1,421	1,389	1,410
(B) Other Equity	6,123	7,527	8,049	(B) Capital Work-in-progress	146	200	254
Total Equity	6,270	7,674	8,196	(C) Right-of-Use Assets	298	364	349
Non-Current Liabilities				(D) Other Intangible Assets	22	19	17
(A) Financial Liabilities				(E) Financial Assets (i) Investments	625	640	656
(i) Borrowings	79	117	209	(ii) Trade Receivables	12	12	12
(ii) Lease Liabilities	46	26	25	(iii) Loans	335	220	220
(iii) Other financial Liabilities	85	89	89	(iv) Other Financial Assets	85	86	77
(B) Provisions	148	166	166	(F) Other Non-Current Assets	35	165	207
Total Non – Current Liabilities	358	398	489	(G) Deferred Tax Assets	42	82	90
Current Liabilities	550	550	-05	Total Non – Current Assets	3,021	3,177	3,292
(A) Financial Liabilities				Current Assets			
(i) Borrowings	228	196	156	(A) Inventories	1,024	1,462	1,982
(ii) Lease Liabilities	59	40	37	(B) Financial Assets			
(iii) Trade Payables	5,045	4,859	4,709	(i) Investments	2	3	3
	263	280		(ii) Trade Receivables	4,528	5,088	5,273
(iv) Other Financial Liabilities			311	(iii) Cash & Cash Equivalents	1,813	1,536	1,208
(B) Other Current Liabilities	2,441	3,014	3373	(iv) Bank Balances	3,057	3,590	3,761
(C) Provisions	46	64	92	(v) Loans	531	763	723
(D) Liabilities for current tax (Net)	246	142	47	(vi) Other Financial Assets (C) Other current assets	99 881	115 933	81
Total Current Liabilities	8,328	8,595	8,725	Total Current Assets	11,935	933 13,490	1,087 <b>14,118</b>
<b>GRAND TOTAL - EQUITIES &amp; LIABILITES</b>	14,956	16,667	17,410	GRAND TOTAL – ASSETS	11,955	16,667	14,118

# Historical Consolidated Financial Performance

INCOME STATEMENT (INR MN)	FY19	FY20	FY21	FY22	H1-FY23
Operating Income	11,623	14,798	14,495	15,769	8,300
Expenses	10,557	13,453	12,472	13,637	7,438
Operating EBITDA	1,066	1,345	2,023	2,132	862
Operating EBITDA Margins (%)	9.17%	9.09%	13.96%	13.52%	10.39%
Depreciation	196	235	277	280	143
Finance Cost	190	160	126	100	45
Other Income	333	354	331	417	230
РВТ	1,013	1,304	1,951	2,169	904
Share of Profit of equity accounted Investee	5	5	(1)	4	6
Тах	359	367	517	556	249
Profit After Tax	659	942	1,433	1,617	661
PAT Margins (%)	5.67%	6.37%	9.89%	10.25%	7.96%
Other Comprehensive Income	1	2	(2)	(10)	12
Total Comprehensive Income	660	944	1,431	1,607	673
EPS Diluted (INR)	56.99*	80.22#	121.41 <sup>@</sup>	137.30 <sup>@</sup>	56.52 <sup>@</sup>

\*Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. No. of Shares- 26,62,914


#Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. No. of Shares-23,68,939

<sup>@</sup>Earnings per equity share includes impact of equity shares held by IEI Shareholding (Staff Welfare) Trusts. & HMIL Shareholding (Staff Welfare) Trusts: (No. of Shares- 23,73,614) and shares held by Subsidiary companies: (No. of Shares- 4,37,874)

# Historical Consolidated Balance Sheet

PARTICULARS (INR MN)	FY21	FY22	H1-FY23	PARTICULARS (INR MN)	FY21	FY22	H1-FY23
EQUITIES & LIABILITIES				ASSETS			
Equity				Non-Current Assets			
(A) Equity Share Capital	142	142	142	(A) Property, Plant and Equipment	1,486	1,446	1,469
(B) Other Equity	4,916	6,414	6,924	(B) Capital Work-in-progress	146	200	254
Equity attributable to owners	5,058	6,556	7,066	(C) Right-of-Use Assets	303	370	352
Non Controlling Interest	(1)	(8)	23	(D) Other Intangible Assets	22	19	18
Total Equity	5,057	6,548	7,089	(E) Goodwill	86	86	86
Non-Current Liabilities				(F) Investment accounted using Equity Method	36	40	46
(A) Financial Liabilities				(G) Financial Assets (i) Investments	7	44	47
(i) Borrowings	79	117	209	(i) Trade Receivables	45	44	47
(ii) Lease liabilities	48	29	28	(iii) Other Financial Assets	177	43	45 159
(iii) Other Financial Liabilities	85	89	89	(H) Deferred Tax Assets (Net)	54	93	100
(B) Provisions	171	191	191	(I) Other Non-Current Assets	135	257	298
(C) Deferred Tax Liabilities (Net)		2	2	(J) Non-Current Tax Assets	6	14	21
(D) Other Non-Current Liabilities	5	5	5	Total Non – Current Assets	2,503	2,785	2,895
Total Non – Current Liabilities	388	433	524	Current Assets	-		
Current Liabilities				(A) Inventories	1,276	1,810	2,331
(A) Financial Liabilities				(B) Financial Assets			
(i) Borrowings	434	364	377	(i) Investments	2	3	3
(ii) Lease liabilities	61	42	38	(ii) Trade Receivables	4,489	5,077	5,236
(iii) Trade Payables	5,353	5,235	5,044	(iii) Cash & Cash Equivalents	1,972	1,691	1,450
(iv) Other Financial Liabilities	311	324	353	(iv) Bank Balances	3,082	3,668	3,843
(B) Other Current Liabilities	2,518	3,085	3,470	(v) Loans	142	201	168
(C) Provisions	53	73	112	(vi) Other Financial Assets	117	137	102
(D) Liabilities for current tax (Net)	258	150	52	(C) Current Tax Assets (Net) (D) Other Current Assets	7	3	2
Total Current Liabilities	8,988	9,273	9,446	Total Current Assets	843 <b>11,930</b>	879	1,029
GRAND TOTAL - EQUITIES & LIABILITES	14,433	16,254	17,059	GRAND TOTAL – ASSETS	14,433	13,469 16,254	14,164 17,059

# **Consolidated Financial Performance**




#### Market Data (Bloomberg – ION IN, Reuters – IONX.BO)

#### 1 YEAR SHARE PRICE MOVEMENT (UP TO 30th September, 2022)



PRICE DATA (As on 30th September, 2022)	
Face value (INR)	10.0
Market Price (INR)	2,151.9
52 Week H/L (INR)	2,442.1/1,500.7
Market Cap (INR Mn)	31,561.2
Equity Shares Outstanding (Mn)	14.7
1 Year Avg. trading volume ('000)	27.8

SHAREHOLDING PATTERN (As on 30th September, 2022)



#### Disclaimer

#### Ion Exchange (India) Limited

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Ion Exchange (India) Limited ("Company" or "IONEX"), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

#### Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.



For further details please contact our Investor Relations Representatives: VALOREM ADVISORS Mr. Anuj Sonpal Tel: +91-22-49039500 Email: jon@valoremadvisors.com

# THANK YOU